Fluent BioSciences awarded $1.7 Million SBIR grant to commercialize PIPseq™, a breakthrough platform technology enabling scalable, sensitive single-cell analysis in any laboratory

WATERTOWN, Mass., March 9, 2022 /PRNewswire/ — Fluent BioSciences, a biotechnology company focused on making single-cell analysis simple and accessible to every researcher, announced today that it has been awarded a $1.7 Million Small Business Innovation Research (SBIR) Phase II grant from the National Institute of General Medical Sciences.  

Fluent BioSciences was established in early 2018 as a spin-out from the laboratory of co-founder Dr. Adam Abate at the University of California San Francisco (UCSF).  Fluent’s breakthrough Pre-templated Instant Partitions (PIPseq™) technology enables near-instantaneous self-assembly of individual cells or molecules into millions of uniform partitions without the need for complex instrumentation or expensive consumables, and is currently in the early access phase of its first product for 3′ Single Cell RNA analysis.

Fluent has now been awarded five NIH grants, in addition to the already successful completion of a $19 million Series A financing round in 2020 led by Illumina Ventures and Samsara BioCapital, two leading firms specializing in early stage life science companies, along with additional investment from Cowin Ventures, VC23 Ventures, and Civilization Ventures.

“Our mission is to accelerate the understanding of biology and disease through accessible, affordable, and scalable single-cell analysis solutions”, stated Sepehr Kiani, co-founder, and CEO of Fluent BioSciences.  “This grant is further validation of our unique technology that finally brings the power of single-cell analysis to every researcher without the burden of high-cost complex instrumentation and one-size fits all consumables.”

About Fluent BioSciences
Fluent BioSciences is a privately funded biotechnology company with a mission to accelerate the understanding of biology and disease through accessible, affordable, and scalable solutions for every laboratory from research to the clinic.  Fluent’s breakthrough Pre-templated Instant Partitions (PIPseq™) technology facilitates near-instantaneous self-assembly of individual cells or molecules into millions of uniform partitions without the need for complex instrumentation or expensive consumables. This powerful platform enables extremely sensitive and unbiased preparation of proteins and nucleic acids for a broad range of discovery and disease applications including single-cell RNA sequencing (scRNA-Seq).

For more information, visit https://www.fluentbio.com/

CONTACT: Ram Santhanam, [email protected]

Cision View original content:https://www.prnewswire.com/news-releases/fluent-biosciences-awarded-1-7-million-sbir-grant-to-commercialize-pipseq-a-breakthrough-platform-technology-enabling-scalable-sensitive-single-cell-analysis-in-any-laboratory-301499389.html

SOURCE Fluent BioSciences

Fluent BioSciences awarded $1.7 Million SBIR grant to commercialize PIPseq™, a breakthrough platform technology enabling scalable, sensitive single-cell analysis in any laboratory WeeklyReviewer

PR Newswire Business News

Earnings Disclosure

WeeklyReviewer earns primarily through affiliates and ads. We don’t encourage anyone to click on ads for any other purpose but your own. We recommend products and services often for our readers, and through many we will earn commissions through affiliate programs.

WeeklyReviewer earns commissions through affiliates of qualifying products through Amazon Associates, Fiverr Affiliates, Hostgator Affiliates, Namecheap Affiliates, NordVPN Affiliates, Semrush Affiliates, Alibaba Affiliates, Clickfunnels Affiliate, Leadpages Affiliates, Cryptohopper Affiliates, Binance Affiliates and more.

Clicking on links in WeeklyReviewer may or may not provide us commission through any qualifying purchases.

World Reviewer Staff
World Reviewer Staffhttps://weeklyreviewer.com/
The first logical thought has to be "no way". I'm the World Observer! Ill find and share important news all day.

Latest articles

Related articles

WeeklyReviewer